|
1
|
Hong SW, Jung KH, Choi MJ, et al:
Anticancer effects of KI-10F: a novel compound affecting apoptosis,
angiogenesis and cell growth in colon cancer. Int J Oncol.
41:1715–1722. 2012.PubMed/NCBI
|
|
2
|
Amsterdam A, Raanan C, Schreiber L,
Freyhan O, Fabrikant Y and Melzer E: Use of multiple biomarkers for
the localization and characterization of colon cancer stem cells by
indirect immunocytochemistry. Int J Oncol. 41:285–291. 2012.
|
|
3
|
Hu Z, Rao B, Chen S and Duanmu J:
Targeting tissue factor on tumour cells and angiogenic vascular
endothelial cells by factor VII-targeted verteporfin photodynamic
therapy for breast cancer in vitro and in vivo in mice. BMC Cancer.
10:2352010. View Article : Google Scholar
|
|
4
|
Rak J, Milsom C, Magnus N and Yu J: Tissue
factor in tumour progression. Best Pract Res Clin Haematol.
22:71–83. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Waxman E, Ross JB, Laue TM, et al: Tissue
factor and its extracellular soluble domain: the relationship
between intermolecular association with factor VIIa and enzymatic
activity of the complex. Biochemistry. 31:3998–4003. 1992.
View Article : Google Scholar
|
|
6
|
Hu Z, Sun Y and Garen A: Targeting tumor
vasculature endothelial cells and tumor cells for immunotherapy of
human melanoma in a mouse xenograft model. Proc Natl Acad Sci USA.
96:8161–8166. 1999. View Article : Google Scholar
|
|
7
|
Tang Y, Borgstrom P, Maynard J, et al:
Mapping of angiogenic markers for targeting of vectors to tumor
vascular endothelial cells. Cancer Gene Ther. 14:346–353. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu Z and Garen A: Targeting tissue factor
on tumor vascular endothelial cells and tumor cells for
immunotherapy in mouse models of prostatic cancer. Proc Natl Acad
Sci USA. 98:12180–12185. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu Z and Garen A: Intratumoral injection
of adenoviral vectors encoding tumor-targeted immunoconjugates for
cancer immunotherapy. Proc Natl Acad Sci USA. 97:9221–9225. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu Z, Rao B, Chen S and Duanmu J:
Selective and effective killing of angiogenic vascular endothelial
cells and cancer cells by targeting tissue factor using a factor
VII-targeted photodynamic therapy for breast cancer. Breast Cancer
Res Treat. 126:589–600. 2011. View Article : Google Scholar
|
|
11
|
Shoji M, Sun A, Kisiel W, et al: Targeting
tissue factor-expressing tumor angiogenesis and tumors with EF24
conjugated to factor VIIa. J Drug Target. 16:185–197. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nemerson Y: Tissue factor and hemostasis.
Blood. 71:1–8. 1988.PubMed/NCBI
|
|
13
|
Ruf W, Kalnik MW, Lund-Hansen T and
Edgington TS: Characterization of factor VII association with
tissue factor in solution. High and low affinity calcium binding
sites in factor VII contribute to functionally distinct
interactions. J Biol Chem. 266:15719–15725. 1991.PubMed/NCBI
|
|
14
|
Toomey JR, Smith KJ and Stafford DW:
Localization of the human tissue factor recognition determinant of
human factor VIIa. J Biol Chem. 266:19198–19202. 1991.PubMed/NCBI
|
|
15
|
Zhang Q, Liu XJ, Hu L, et al: Factor VII
light chain-targeted lidamycin targets tissue factor-overexpressing
tumor cells for cancer therapy. Int J Mol Med. 29:409–415.
2012.PubMed/NCBI
|
|
16
|
Allen TM: Ligand-targeted therapeutics in
anticancer therapy. Nat Rev Cancer. 2:750–763. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
He QY, Liang YY, Wang DS and Li DD:
Characteristics of mitotic cell death induced by enediyne
antibiotic lidamycin in human epithelial tumor cells. Int J Oncol.
20:261–266. 2002.PubMed/NCBI
|
|
18
|
Guo XF, Zhu XF, Shang Y, Zhang SH and Zhen
YS: A bispecific enediyne-energized fusion protein containing
ligand-based and antibody-based oligopeptides against epidermal
growth factor receptor and human epidermal growth factor receptor 2
shows potent antitumor activity. Clin Cancer Res. 16:2085–2094.
2010. View Article : Google Scholar
|
|
19
|
Zhang Q, Liu X, Xu S, et al: Factor VII
light chain-targeted lidamycin shows intensified therapeutic
efficacy for liver cancer. Cancer Biother Radiopharm. 27:384–391.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Drake TA, Morrissey JH and Edgington TS:
Selective cellular expression of tissue factor in human tissues.
Implications for disorders of hemostasis and thrombosis. Am J
Pathol. 134:1087–1097. 1989.PubMed/NCBI
|
|
21
|
Wilcox JN, Smith KM, Schwartz SM and
Gordon D: Localization of tissue factor in the normal vessel wall
and in the atherosclerotic plaque. Proc Natl Acad Sci USA.
86:2839–2843. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu Z, Rao B, Chen S and Duanmu J:
Selective and effective killing of angiogenic vascular endothelial
cells and cancer cells by targeting tissue factor using a factor
VII-targeted photodynamic therapy for breast cancer. Breast Cancer
Res Treat. 126:589–600. 2011. View Article : Google Scholar
|
|
23
|
Senger DR, Galli SJ, Dvorak AM, Perruzzi
CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular
permeability factor that promotes accumulation of ascites fluid.
Science. 219:983–985. 1983. View Article : Google Scholar
|
|
24
|
Xin C, Ye S, Ming Y, et al: Efficient
inhibition of B-cell lymphoma xenografts with a novel recombinant
fusion protein: anti-CD20Fab-LDM. Gene Ther. 17:1234–1243. 2010.
View Article : Google Scholar : PubMed/NCBI
|
